Dana-Farber Cancer Institute: Antibody-Drug Conjugate Shows Impressive Activity in Patients With Non-Small Cell Lung Cancer With HER2 Gene Mutation
September 20, 2021
September 20, 2021
BOSTON, Sept. 20 -- The Dana-Farber Cancer Institute issued the following news release on Sept. 18, 2021:
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
The results, to . . .
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
The results, to . . .